Pfizer Calls For Fees On US Merck Pneumonia Vaccine At Trial

Law360, London (June 30, 2020, 8:20 PM BST) -- Pfizer kicked off a London trial against Merck Sharp & Dohme on Tuesday by saying the rival pharmaceutical company's proposed pneumonia vaccine infringes its Prevenar 13 patent, meaning the U.S. drugmaker should pay for use of its technology.

Though Merck Sharp & Dohme Corp. first brought the suit seeking to invalidate Pfizer's patents for being obvious, only Pfizer's attorney made opening remarks at the start of the six-day High Court trial over the patent, which addresses a problem caused by the silicon in syringes by using an aluminum salt to increase the body's immune response.

Pfizer's counsel, Michael Tappin QC of 8...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!